Ansa Biotechnologies on Nov. 18 announced the close of a $71.5 million Series C financing, bringing its total funding to $211 million.
Blue Water Life Science Advisors led the round. New investors include Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital; existing investors also taking part include Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures.
The company said it quadrupled its manufacturing capacity over the past year and will use the new funds to further expand capacity and serve more customers.
In connection with their investments, Illumina Ventures Partner Nick Naclerio and Blue Water Chief Investment Officer Nate Cornell have joined Ansa’s board. Ansa also added Brad Crutchfield, a life science tools industry veteran with experience at 10x Genomics and Bio-Rad Laboratories, also joined as an independent director. Matthew McManus is stepping down from the board.
“The full potential of AI-enabled biology depends on the ability to build and test what computational models design,” Naclerio said in a statement. “Ansa gives researchers access to DNA that has historically been difficult, if not impossible, to obtain, with a delivery commitment they can plan around. That combination of technical capability and commercial execution is why we invested.”
Bay Area-based Ansa makes synthetic DNA using a proprietary enzymatic synthesis platform. It sells clonal DNA up to 50 Kb as well as linear double-stranded DNA fragments.

